Gunderson Dettmer Advises Aldeyra Therapeutics on Public Offering

October 10, 2018Client News

Gunderson Dettmer advised Aldeyra Therapeutics, Inc. on a follow-on public offering of 5,250,000 shares at the price to the public of $13.75 per share for a total of $72,187,500 in aggregate gross proceeds. Corporate partner Jay Hachigian, of counsel Keith Scherer, and associates Albert Vanderlaan, Naomi Smith and John Maciejewski led the team advising Aldeyra.

Citigroup acted as lead bookrunning manager for the offering. Cantor Fitzgerald & Co. also acted as a bookrunning manager. Laidlaw & Company (UK) Ltd., Janney Montgomery Scott and JonesTrading acted as co-managers.

Aldeyra, which trades on The Nasdaq Capital Market under the ticker symbol “ALDX,” is a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases.